Skip to content
Unrated Drug recall · FDA · Published July 27, 2023

Alembic Tobramycin Ophthalmic Solution Recall: Impurities Risk

Alembic Pharmaceuticals recalls Tobramycin Ophthalmic Solution 0.3% 5mL bottles due to failed impurities and degradation specifications. Rx only product with specific lot numbers and expiration dates.

🇺🇸 FDA recall #D-1086-2023DrugAlembic Pharmaceuticals ›
Take action

Contact the company

Recalling firmALEMBIC PHARMACEUTICALS, INC.550 Hills Dr Ste 104b · Bedminster, NJ 07921-1537
✎ GovInfoNow plain-language explainer

Alembic Pharmaceuticals is recalling Tobramycin Ophthalmic Solution 0.3% 5mL bottles because they may contain impurities or degrade improperly. This could pose a risk to users who need this medication for eye infections. Read more at govinfonow.com/recall/33233-alembic-tobramycin-ophthalmic-solution-recall-impurities-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/33233-alembic-tobramycin-ophthalmic-solution-recall-impurities-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-1086-2023

Cite this page

“Alembic Tobramycin Ophthalmic Solution Recall: Impurities Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/33233-alembic-tobramycin-ophthalmic-solution-recall-impurities-risk. Based on FDA recall #D-1086-2023 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1086-2023%22&limit=1).

Alembic Pharmaceuticals voluntarily recalled Tobramycin Ophthalmic Solution USP, 0.3%, 5mL bottles due to failed impurities and degradation specifications, the FDA announced on July 27, 2023. The recall affects 82,400 bottles distributed nationwide.

How to tell if you have it

  • Brand: Alembic Pharmaceuticals
  • Product: Tobramycin Ophthalmic Solution USP, 0.3%, 5mL bottle, Rx only
  • NDC: 62332-518-05
  • Lot codes: AMR103 (Exp: 10/2023), AMR201 (Exp: 06/2024)
  • Manufacturer: Alembic Pharmaceuticals, Bedminster, NJ 07921, USA

The hazard

The product failed impurities and degradation specifications. The FDA classified the recall as Class III.

Context

GovInfoNow's records show Alembic Pharmaceuticals has one other recall on record since June 22, 2023: a June 22, 2023 recall of Diclofenac Topical Solution for defective delivery system risk. Other recent recalls of similar products include an August 27, 2026 recall of Macleods Olanzapine Tablets 5mg for impurities that may cause harm, a November 26, 2025 recall of Sun Pharmaceutical Clindamycin Phosphate Topical Solution for impurity risk, and a December 16, 2025 recall of Alembic Fesoterodine Tablets for diester impurity risk.

How to tell if you have this one

Check for the product name 'Tobramycin Ophthalmic Solution USP 0.3% 5mL', manufactured by Alembic Pharmaceuticals in Bedminster, NJ. Look for lot numbers AMR103 (expiring 10/2023) or AMR201 (expiring 06/2024).

  • Brand
    Alembic Pharmaceuticals
  • Category
    Drug
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the product name, lot number, and expiration date to confirm if it's recalled.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 27 days after the firm started it.

1. Firm started the recall: Jul 27, 202312. FDA classified it Class III: Aug 17, 202323. Published in FDA’s Enforcement Report: Aug 23, 202332023
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-1086-2023 (July 27, 2023) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-1086-2023 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA